# NCT02231749 (NCT02231749)

> Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02231749
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
- Interventions: Nivolumab; Ipilimumab; Sunitinib
- Enrollment: 1096
- Primary outcome: Objective Response Rate (ORR) in Intermediate/Poor Risk Participants Per Independent Radiology Review Committee (IRRC) Using RECIST v1.1
- Primary outcome: Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)
- Primary outcome: Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)

## Commentary we found

- YouTube: 72
- Podcasts: 72
- X threads: 68
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02231749

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02231749", "email": "<work email>"}; the inbox owner confirms by the emailed link.